Application of quaternized U50 and 488H in preparation of medicine for treating vascular calcification

The invention belongs to the technical field of medicines, and particularly relates to application of quaternized U50 and 488H in preparation of a medicine for treating vascular calcification. The quaternized U50 and 488H are obtained by quaternized modification of kappa-opioid receptor stimulants U50 and 488H, the research result proves that the vascular calcification inhibition effect of the quaternized U50 and 488H is stronger than that before modification, opioid substance addiction caused by a blood brain barrier can be avoided, the potential drug safety problem is eliminated, and the application prospect is wide. The invention also provides a development and application approach for preparing drugs for inhibiting vascular calcification and treating vascular calcification. 本发明属于医药技术领域，具体涉及季胺化U50,488H在制备用于治疗血管钙化的药物中的用途。所述季胺化U50,488H是由κ-阿片受体激动剂U50,488H经季胺化改造获得，本发明研究结果证实，季胺化U50,488H抑制血管钙化的作用强于改造前，且能够避免通过血脑屏障引起阿片类物质的成瘾，排除了潜在的药物安全性问题，本发明为制备抑制血管钙化的药物和治疗血管钙化又提供了一条开发和应用的途径。